

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the “Shanghai Junshi Biosciences Co., Ltd.* 2024 Third Quarterly Report” published by Shanghai Junshi Biosciences Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for reference purpose only. The unaudited financial data set out in this announcement is prepared in accordance with the accounting principles of the People’s Republic of China instead of the International Financial Reporting Standards, and is prepared pursuant to the requirements of the STAR Market of the Shanghai Stock Exchange only. The following is a translation of the 2024 Third Quarterly Report of the Company solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

Shareholders and potential investors are advised to exercise caution when dealing in securities of the Company.

By Order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, PRC, 29 October 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Yao Sheng, Dr. Wang Gang and Dr. Li Xin as executive Directors; Mr. Tang Yi as non-executive Director; and Mr. Zhang Chun, Dr. Feng Xiaoyuan, Dr. Meng Anming, and Dr. Yang Yue as independent non-executive Directors.

* For identification purpose only

Stock code: 688180

Abbreviation: Junshi Bio

Shanghai Junshi Biosciences Co., Ltd.*

2024 Third Quarterly Report

The board of directors and all directors of the Company warrant that the contents of the announcement do not contain any false and misleading representation or material omission, and shall undertake legal liabilities in accordance with the law for the truthfulness, accuracy and completeness of the contents herein.

IMPORTANT NOTICE:

The board of directors, the board of supervisors and the directors, supervisors and senior management of the Company undertake that the information in this quarterly report is true, accurate and complete, and contains no false record, misleading statement or material omission, and assume several and joint liabilities in respect of the information in this report.

The person in charge of the Company, the person in charge of accounting affairs, and the person in charge of the accounting office (head of accounting department), hereby guarantee that the financial statements contained in this quarterly report are true, accurate and complete.

Whether the financial statements contained in this third quarterly report have been audited

Yes No

I. Key Financial Data

(I) Key accounting data and financial indicators

Unit: Yuan Currency: RMB

Item	During the reporting period	Change year-on-year (%)	From the beginning of the year to the end of the reporting period	Change year-on-year (%)

Operating income	485,143,734.52	53.16	1,271,200,009.95	28.87
Net loss attributable to shareholders of the Company	-281,813,873.94	N/A	-926,768,557.18	N/A
Net loss attributable to shareholders of the Company after deducting non-recurring profit and loss	-312,608,905.73	N/A	-939,839,865.37	N/A
Net cash flow from operating activities	N/A	N/A	-1,113,472,084.61	N/A
Basic earnings per share (Yuan/share)	-0.29	N/A	-0.94	N/A
Diluted earnings per share (Yuan/share)	-0.29	N/A	-0.94	N/A
Weighted average return on net assets (%)	-4.45	Increased by 0.46 percentage point	-13.91	Increased by 2.04 percentage points
Total research and development investment	327,892,775.06	1.82	874,268,925.53	-31.19
Research and development investment as a percentage of operating income (%)	67.59	Decreased by 34.07 percentage points	68.78	Decreased by 60.03 percentage points
	As at the end of the reporting period	As at the end of the previous year		Increase/decrease at the end of the reporting period compared with the end of the previous year (%)
Total assets	10,857,613,524.70		11,342,866,871.33	-4.28

Owners' equity attributable to the shareholders of the Company	6,172,509,756.39	7,151,224,186.47	-13.69
--	------------------	------------------	--------

Note: The “reporting period” refers to the period of three months commencing from the beginning of this quarter to the end of this quarter, the same for below.

(II) Non-recurring gains and losses items and amounts

√ Applicable □ Not applicable

Unit: Yuan Currency: RMB

Non-recurring gains and losses item	Amount for the reporting period	Amount for the period from the beginning of the year to the end of the reporting period	Note
Gains or losses from the disposal of non-current assets, including write-off of provision for asset impairment	2,371,837.98	14,691,545.93	Nil
Government grants that are recognized in profit or loss for the period (other than government grants which are closely related to the Company's normal business operations, comply with national policies, conform with established standards and have a lasting impact on the Company's profits or losses)	37,587,565.07	47,525,736.73	Nil
Gains or losses on changes in fair value arising from holding financial assets and liabilities by non-financial enterprises, as well as gains or losses from disposal of financial assets and liabilities, except for effective hedging transactions related to the Company's normal business operations	6,539,517.61	-25,219,188.40	Nil
Other non-operating income and expenses apart from the aforesaid items	-7,005,832.87	-14,859,561.94	Nil
Less: Effect of income tax	250,531.27	743,552.27	Nil
Effect of minority interests (after tax)	8,447,524.73	8,323,671.86	Nil
Total	30,795,031.79	13,071,308.19	Nil

Description on the reasons for recognizing items not set out in the “Explanatory Announcement No. 1 Regarding Information Disclosure for Companies Publicly Issuing Securities - Non-recurring Gains or Losses”* (《公開發行證券的公司信息披露解釋性公告第 1 號——非經常性損益》) as non-recurring gains or losses items and the amounts of which are significant, and defining the non-recurring gains or losses items set out in the “Explanatory Announcement No. 1 Regarding Information Disclosure for

Companies Publicly Issuing Securities - Non-recurring Gains or Losses”*(《公開發行證券的公司信息披露解釋性公告第 1 號——非經常性損益》) as recurring gains or losses items by the Company

Applicable Not applicable

(III) Descriptions and reasons for changes in major accounting data and financial indicators

Applicable Not applicable

Item	Change (%)	Major reason
Operating income_for the reporting period	53.16	Mainly due to the growth of sales revenue of commercialized drugs of the Company compared with the same period of the previous year, and with a number of clinical trials of the Company’s core product TUOYI® meeting the primary endpoints and the implementation of the “Quality Improvement, Efficiency Enhancement and Focus on Returns” Action Plan, the company kept enhancing management and control of expenses, devoted its resources to research and development projects with greater potential, which led to a decrease in loss.
Net loss attributable to shareholders of the Company_for the reporting period	N/A	
Net loss attributable to shareholders of the Company_from the beginning of the year to the end of the reporting period	N/A	
Net loss attributable to the shareholders of the Company after deducting non-recurring profit and loss_from the beginning of the year to the end of the reporting period	N/A	
Net cash flow from operating activities_from the beginning of the year to the end of the reporting period	N/A	
Basic earnings per share (Yuan/share)_for the reporting period	N/A	
Basic earnings per share (Yuan/share)_from the beginning of the year to the end of the reporting period	N/A	
Diluted earnings per share (Yuan/share)_for the reporting period	N/A	
Diluted earnings per share (Yuan/share)_from the beginning of the year to the end of the reporting period	N/A	

Total research and development investment from the beginning of the year to the end of the reporting period	-31.19	
Research and development investment as a percentage of operating income (%) for the reporting period	Decreased by 34.07 percentage points	
Research and development investment as a percentage of operating income (%) from the beginning of the year to the end of the reporting period	Decreased by 60.03 percentage points	

II. Shareholder Information

(I) Particulars of total number of ordinary shareholders and preferred shareholders with voting rights restored and shareholding of top ten shareholders

Unit: Share

Total number of holders of ordinary shares as at the end of the reporting period	29,498	Total number of preferred shareholders with voting rights restored as at the end of the reporting period (if any)	N/A				
Particulars of shareholding of the top 10 shareholders (excluding the shares lent under securities refinancing)							
Name of shareholder	Type of shareholder	Number of shares held	Shareholding percentage (%)	Number of shares held subject to trading restrictions	Number of restricted shares including shares lent for securities refinancing	Pledged, marked or frozen shares	
						Status of shares	Number of shares
HKSCC NOMINEES LIMITED	Unknown	219,291,210	22.25	0	0	Unknown	-
Xiong Jun	Domestic natural person	87,854,018	8.91	0	0	Nil	0
Shanghai Tanying Investment Partnership (LP)*(上海檀英投資合夥企業(有限合夥))	Others	76,590,000	7.77	0	0	Nil	0

Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)* (蘇州瑞源盛本生物醫藥管理合夥企業 (有限合夥))	Others	43,584,000	4.42	0	0	Nil	0
China Merchants Bank Co., Ltd. - Huaxia SSE STAR Market 50 Constituent Traded Open-ended Index Securities Investment Fund* (招商銀行股份有限公司－華夏上證科創板 50 成份交易型開放式指數證券投資基金)	Others	42,112,468	4.27	0	0	Nil	0
Xiong Fengxiang	Domestic natural person	41,060,000	4.17	0	0	Nil	0
Industrial and Commercial Bank of China Limited – E Fund SSE STAR 50 Constituent Traded Open-ended Index Securities Investment Fund* (中國工商銀行股份有限公司－易方達上證科創板 50 成份交易型開放式指數證券投資基金)	Others	25,295,724	2.57	0	0	Nil	0
Zhou Yuqing	Domestic natural person	21,680,800	2.20	0	0	Nil	0
Hong Kong Securities Clearing Company Limited	Foreign legal person	16,144,066	1.64	0	0	Nil	0
Feng Hui	Domestic natural person	13,180,000	1.34	0	0	Nil	0
Particulars of shareholdings of the top 10 shareholders not subject to trading restrictions (excluding the shares lent under securities refinancing)							
Name of shareholder	Number of tradable shares held not subject to trading restrictions	Type and number of shares					
		Type of shares	Number of shares				
HKSCC NOMINEES LIMITED	219,291,210	Overseas listed foreign shares	219,291,210				

Xiong Jun	87,854,018	RMB ordinary shares	87,854,018
Shanghai Tanying Investment Partnership (LP)* (上海檀英投資合夥企業 (有限合夥))	76,590,000	RMB ordinary shares	76,590,000
Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)* (蘇州瑞源盛本生物醫藥管理合夥企業 (有限合夥))	43,584,000	RMB ordinary shares	43,584,000
China Merchants Bank Co., Ltd. - Huaxia SSE STAR Market 50 Constituent Traded Open-ended Index Securities Investment Fund* (招商銀行股份有限公司—華夏上證科創板 50 成份交易型開放式指數證券投資基金)	42,112,468	RMB ordinary shares	42,112,468
Xiong Fengxiang	41,060,000	RMB ordinary shares	41,060,000
Industrial and Commercial Bank of China Limited – E Fund SSE STAR 50 Constituent Traded Open-ended Index Securities Investment Fund* (中國工商銀行股份有限公司—易方達上證科創板 50 成份交易型開放式指數證券投資基金)	25,295,724	RMB ordinary shares	25,295,724
Zhou Yuqing	21,680,800	RMB ordinary shares	21,680,800
Hong Kong Securities Clearing Company Limited	16,144,066	RMB ordinary shares	16,144,066
Feng Hui	13,180,000	RMB ordinary shares	13,180,000

<p>Description of the related party relationship or acting-in-concert arrangement among the above shareholders</p>	<p>Among the above shareholders, Xiong Fengxiang and Xiong Jun have a father-son relationship and are the controlling shareholders and actual controllers of the Company. Xiong Jun and Xiong Fengxiang are acting in concert with Suzhou Ruiyuan Shengben Biological Medicine Management Partnership (LP)* (蘇州瑞源盛本生物醫藥管理合夥企業 (有限合夥)) (“Ruiyuan Shengben”) and Zhou Yuqing. Xiong Jun holds 40% of the equity interest in Shenzhen Qianhai Yuanben Equity Investment Fund Management Co., Ltd.* (深圳前海源本股權投資基金管理有限公司), being Ruiyuan Shengben’s managing partner. Ruiyuan Shengben is held as to 5.1% by Zhou Yuqing. Save for the above description, the Company is not aware as to whether the other shareholders have related party relationship or whether the other shareholders are acting-in-concert parties under relevant regulations.</p>
<p>Description on the top 10 shareholders and the top 10 shareholders not subject to trading restrictions engaging in margin trading and securities refinancing, if any</p>	<p>As of the end of the reporting period, the aforementioned shareholders did not participate in margin trading or short selling. All the shares lent by the relevant shareholders for refinancing transactions have been returned. For details, please see below.</p>

Note 1: As at the end of the reporting period, among all the ordinary shareholders, there are 29,489 holders of A shares and 9 holders of H shares, amounting to a total of 29,498 shareholders;

Note 2: HKSCC NOMINEES LIMITED holds shares on behalf of various clients.

Shares lent by shareholders interested in more than 5% of the shares, top 10 shareholders and top 10 shareholders not subject to trading restrictions for securities refinancing

√ Applicable □ Not applicable

Unit: Share

Shares lent by shareholders interested in more than 5% of the shares, top 10 shareholders and top 10 shareholders not subject to trading restrictions for securities refinancing								
Name of shareholder (in full)	Shareholding through ordinary securities account and margin account at the beginning of the period		Shares lent for securities refinancing and not yet returned at the beginning of the period		Shareholding through ordinary securities account and margin account at the end of the period		Shares lent for securities refinancing and not yet returned at the end of the period	
	Total number	Percent age (%)	Total number	Percent age (%)	Total number	Percent age (%)	Total number	Percent age (%)
China Merchants Bank Co., Ltd. - Huaxia SSE STAR Market 50 Constituent Traded	38,594,237	3.92	729,200	0.07	42,112,468	4.27	0	0

Open-ended Index Securities Investment Fund* (招商銀行股份有限公司—華夏上證科創板 50 成份交易型開放式指數證券投資基金)									
Industrial and Commercial Bank of China Limited – E Fund SSE STAR 50 Constituent Traded Open-ended Index Securities Investment Fund* (中國工商銀行股份有限公司—易方達上證科創板 50 成份交易型開放式指數證券投資基金)	12,812,703	1.30	253,400	0.03	25,295,724	2.57	0	0	

Change in top 10 shareholders and top 10 shareholders not subject to trading restrictions as compared to the prior period due to lending/returning of shares for securities refinancing

Applicable Not applicable

III. Other Significant Information

Other significant information about the operations of the Company during the reporting period that requires investors' attention

Applicable Not applicable

From the beginning of the year to the end of the reporting period, the growth of the operating revenue of the Company was primarily attributable to the growth of sales revenue of commercialized drugs. In particular, the core product, TUOYI® (toripalimab, product code: JS001) recorded sales revenue of approximately RMB1,068 million in the domestic market, representing a year-on-year increase of approximately 60%. In the third quarter of 2024, TUOYI® recorded sales revenue of approximately RMB397 million in the domestic market, representing a year-on-year increase of approximately 79%. At the same time, the Company strengthened the management and control of various expenses, and devoted its resources to research and development projects with greater potential, which contributed to the decrease

of loss. As of the end of the reporting period, the Company's cash and cash equivalents and financial assets for trading had a total balance of RMB3,045 million, demonstrating relatively sufficient capital reserves.

During the reporting period, the supplemental new drug application (“sNDA”) for toripalimab in combination with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma as well as the sNDA for toripalimab as the first-line treatment for unresectable or metastatic melanoma were accepted by the National Medical Products Administration (“NMPA”); the European Commission (EC) approved toripalimab for the treatment of two indications: toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma, and toripalimab in combination with cisplatin and paclitaxel for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma. As of the date of this report, toripalimab has 10 indications approved in Chinese mainland, and has been approved for marketing in Hong Kong SAR, China, the United States, the European Union, India and other countries and regions. With the expanded indications of toripalimab in the National Reimbursement Drug List, the successive data readouts and approvals of more indications, as well as continuous commercialization expansion in global markets, the commercialization competitiveness of toripalimab will continue to improve.

In terms of other pipelines, from the beginning of the reporting period to the date of this report, ongericimab injection (a recombinant human anti-PCSK9 monoclonal antibody injection, trade name: JUNSHIDA (君適達®)) was approved for marketing by the NMPA for the treatment of adult patients with primary hypercholesterolemia (non-familial) and mixed dyslipidemia; the investigational new drug application for WJ47156 tablets (a targeted histone deacetylases (HDACs) inhibitor, project code: JS125) was approved by the NMPA.

The Company will accelerate the development and marketing application for late-stage pipelines, including the anti-tumor anti-BTLA monoclonal antibody tificemalimab (code: TAB004/JS004) and the anti-IL-17A monoclonal antibody (project code: JS005), and will also continue to explore early-stage pipelines, including the Claudin18.2 ADC drug (code: JS107), the oral small molecule inhibitor targeting PI3K- α (code: JS105), the CD20/CD3 bispecific antibody (code: JS203), the PD-1/VEGF bispecific antibody (code: JS207) and the anti-DKK1 monoclonal antibody (code: JS015), in an effort to push more advantageous products and indications into registrational clinical studies as soon as possible, so as to

facilitate the sustainable growth of the operating revenue of the Company in future.

IV. Quarterly Financial Statements

(I) Types of audit opinion

Applicable Not applicable

(II) Financial statements

CONSOLIDATED BALANCE SHEET

30 September 2024

Prepared by: Shanghai Junshi Biosciences Co., Ltd.*

Unit: Yuan Currency: RMB Audit type: Unaudited

Item	30 September 2024	31 December 2023
Current assets:		
Cash and bank balances	2,474,595,086.04	3,788,193,376.77
Financial assets for trading	570,000,000.00	-
Accounts receivable	466,688,600.66	483,226,004.74
Prepayments	283,147,433.17	238,897,466.48
Other receivables	201,570,630.64	374,008,655.77
Including: Interests receivable	-	-
Dividends receivable	-	-
Inventories	567,442,634.42	538,052,813.07
Including: Data resources	-	-
Non-current assets due within one year	4,746,758.42	8,184,311.36
Other current assets	17,334,532.51	140,512,460.52
Total current assets	4,585,525,675.86	5,571,075,088.71
Non-current assets:		
Long-term equity investments	228,455,933.85	242,575,715.18
Investments in other equity instruments	43,570,437.54	84,184,097.91
Other non-current financial assets	825,298,707.07	806,351,904.77
Fixed assets	2,315,877,222.08	2,431,855,834.52
Construction in progress	1,693,261,195.29	1,325,356,972.04
Right-of-use-assets	50,607,736.54	51,367,618.58
Intangible assets	526,498,411.05	546,964,593.08
Including: Data resources	-	-
Long-term prepaid expenses	8,015,516.26	12,598,552.14
Deferred tax assets	103,204,370.54	103,396,116.17
Other non-current assets	477,298,318.62	167,140,378.23
Total non-current assets	6,272,087,848.84	5,771,791,782.62
Total assets	10,857,613,524.70	11,342,866,871.33
Current liabilities:		

Short-term borrowings	631,656,782.41	452,435,151.72
Notes payable	-	4,672,296.11
Accounts payable	984,192,219.84	1,381,144,867.05
Contract liabilities	162,981,528.94	146,298,445.27
Payroll payable	232,595,559.68	234,201,628.25
Taxes payable	35,574,827.08	50,741,556.79
Other payables	36,180,635.11	37,330,788.82
Including: Interests payable	-	-
Dividends payable	-	-
Non-current liabilities due within one year	213,788,135.65	122,886,665.63
Other current liabilities	617.73	8,686,175.91
Total current liabilities	2,296,970,306.44	2,438,397,575.55
Non-current liabilities:		
Long-term borrowings	1,905,722,659.97	1,195,794,059.52
Lease liabilities	24,796,059.18	17,451,499.85
Provisions	17,624,701.47	27,104,611.58
Deferred income	175,543,917.69	183,463,569.04
Other non-current liabilities	157,015,405.56	160,045,083.81
Total non-current liabilities	2,280,702,743.87	1,583,858,823.80
Total liabilities	4,577,673,050.31	4,022,256,399.35
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	985,689,871.00	985,689,871.00
Capital reserve	15,394,559,338.20	15,394,559,338.20
Less: Treasury shares	30,892,473.08	26,891,299.08
Other comprehensive income	-190,011,657.50	-142,066,958.60
Retained earnings	-9,986,835,322.23	-9,060,066,765.05
Total owners' equity (or shareholders' equity) attributable to the parent company	6,172,509,756.39	7,151,224,186.47
Minority interests	107,430,718.00	169,386,285.51
Total owners' equity (or shareholders' equity)	6,279,940,474.39	7,320,610,471.98
Total liabilities and owners' equity (or shareholders' equity)	10,857,613,524.70	11,342,866,871.33

Legal Representative:
Xiong Jun

Chief Financial Officer:
Xu Baohong

Head of Accounting Department:
Cai Jingwu

CONSOLIDATED INCOME STATEMENT

January to September 2024

Prepared by: Shanghai Junshi Biosciences Co., Ltd.*

Unit: Yuan Currency: RMB Audit type: Unaudited

Item	First three quarters of 2024 (January to September)	First three quarters of 2023 (January to September)
I. Total operating income	1,271,200,009.95	986,457,567.67
Including: Operating income	1,271,200,009.95	986,457,567.67
II. Total operating costs	2,261,152,311.32	2,479,371,840.85
Including: Operating costs	325,339,075.87	336,845,004.30
Taxes and surcharges	17,132,866.24	13,435,038.40
Selling and distribution expenses	683,629,829.87	554,408,514.86
Administrative expenses	353,242,444.41	359,400,187.23
Research and development expenses	874,268,925.53	1,270,626,649.07
Financial expenses	7,539,169.40	-55,343,553.01
Including: Interest expenses	32,912,225.93	19,975,951.59
Interest income	32,647,344.93	77,612,046.32
Add: Other income	47,607,041.87	39,025,160.64
Investment income (Loss is indicated by “-”)	-17,147,524.18	-44,866,462.66
Including: Income from investments in associates and joint ventures	-24,444,582.77	-49,100,983.21
Gain from changes in fair value (Loss is indicated by “-”)	-30,053,190.85	-45,848,211.85
Impairment loss of credit (Loss is indicated by “-”)	11,174,765.63	-1,113,612.12
Impairment loss of assets (Loss is indicated by “-”)	-3,641,769.04	-35,245,743.13
Gains from disposal of assets (Loss is indicated by “-”)	12,891,972.67	600,424.64
III. Operating profit (Loss is indicated by “-”)	-969,121,005.27	-1,580,362,717.66
Add: Non-operating income	877,766.70	3,928,909.10
Less: Non-operating expenses	16,400,811.52	31,081,561.88
IV. Total profit (Total loss is indicated by “-”)	-984,644,050.09	-1,607,515,370.44
Less: Income tax expenses	4,081,640.85	-52,386,479.09
V. Net profit (Net loss is indicated by “-”)	-988,725,690.94	-1,555,128,891.35
(I) Categorized by the nature of continuing operation		
1. Net profit from continuing operations (Net loss is indicated by “-”)	-988,725,690.94	-1,555,128,891.35
2. Net profit from discontinued operations (Net loss is indicated by “-”)	-	-

(II) Categorized by ownership		
1. Net profit attributable to the parent company (Net loss is indicated by “-”)	-926,768,557.18	-1,406,818,402.73
2. Profit or loss attributable to minority shareholders (Net loss is indicated by “-”)	-61,957,133.76	-148,310,488.62
VI. Other comprehensive income, net of tax	-47,944,698.90	-50,732,766.43
(I) Other comprehensive income attributable to the parent company, net of tax	-47,944,698.90	-50,732,766.43
1. Other comprehensive income that cannot be subsequently reclassified to profit or loss	-40,613,660.37	-70,541,152.88
(1) Changes of the re-measurement in defined benefit plans	-	-
(2) Other comprehensive income that cannot be subsequently reclassified to profit or loss under the equity method	-	-
(3) Changes in fair value of investments in other equity instruments	-40,613,660.37	-70,541,152.88
(4) Changes in fair value of the enterprise’s own credit risk	-	-
2. Other comprehensive income that will be reclassified to profit or loss	-7,331,038.53	19,808,386.45
(1) Other comprehensive income that will be reclassified to profit or loss under the equity method	-	-
(2) Changes in fair value of other debt investments	-	-
(3) Amount of financial assets that are reclassified to other comprehensive income	-	-
(4) Impairment provision for credit of other debt investments	-	-
(5) Cash flow hedge reserves	-	-
(6) Exchange differences of financial statements denominated in foreign currencies	-7,331,038.53	19,808,386.45
(7) Others	-	-
(II) Other comprehensive income attributable to minority shareholders, net of tax	-	-

VII. Total comprehensive income	-1,036,670,389.84	-1,605,861,657.78
(I) Total comprehensive income attributable to the parent company	-974,713,256.08	-1,457,551,169.16
(II) Total comprehensive income attributable to minority shareholders	-61,957,133.76	-148,310,488.62
VIII. Earnings per share:		
(I) Basic earnings per share (Yuan/share)	-0.94	-1.43
(II) Diluted earnings per share (Yuan/share)	-0.94	-1.43

In respect of the merger of entities under common control that occurred during the current period, net profit of the entity being merged realized before the merger was nil. Net profit of the entity being merged realized during the previous period was nil.

Legal Representative:
Xiong Jun

Chief Financial Officer:
Xu Baohong

Head of Accounting Department:
Cai Jingwu

CONSOLIDATED STATEMENT OF CASH FLOW

January to September 2024

Prepared by: Shanghai Junshi Biosciences Co., Ltd.*

Unit: Yuan Currency: RMB Audit type: Unaudited

Item	First three quarters of 2024 (January to September)	First three quarters of 2023 (January to September)
I. Cash flow from operating activities:		
Cash received from the sale of goods and the rendering of services	1,334,950,275.33	994,903,657.69
Receipts of tax refunds	10,546,104.09	143,929,288.86
Other cash received in respect of operating activities	51,386,223.25	97,647,401.24
Sub-total of cash inflow from operating activities	1,396,882,602.67	1,236,480,347.79
Cash payments for goods purchased and services received	1,319,202,006.33	1,648,909,781.58
Cash payments to and on behalf of employees	929,835,245.36	958,338,967.96
Payments of various types of taxes	69,060,203.94	58,013,895.34
Other cash payments relating to operating activities	192,257,231.65	235,331,895.56
Sub-total of cash outflow from operating activities	2,510,354,687.28	2,900,594,540.44
Net cash flow from operating activities	-1,113,472,084.61	-1,664,114,192.65

II. Cash flow from investing activities:		
Cash received from recovery of investments	901,371,865.77	1,205,410,678.81
Cash received from investment income	4,834,002.45	4,234,520.55
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	1,865,000.00	22,123.89
Other cash received in respect of investing activities	33,177,403.78	81,168,910.79
Sub-total of cash inflow from investing activities	941,248,272.00	1,290,836,234.04
Cash payments to acquire or construct fixed assets, intangible assets and other long-term assets	620,759,009.17	604,662,480.18
Cash paid for investments	1,404,000,012.50	1,340,008,000.00
Sub-total of cash outflow from investing activities	2,024,759,021.67	1,944,670,480.18
Net cash flow from investing activities	-1,083,510,749.67	-653,834,246.14
III. Cash flow from financing activities:		
Cash received from investors	1,566.25	155,594,530.50
Including: Cash received from capital contributions by minority shareholders of subsidiaries	1,566.25	3,000,000.00
Cash received from borrowings	1,928,788,474.47	602,682,782.88
Other cash received in respect of financing activities	4,641,807.39	179,512,525.12
Sub-total of cash inflow from financing activities	1,933,431,848.11	937,789,838.50
Cash repayments of borrowings	943,497,136.23	389,228,852.72
Cash payments for distribution of dividends, or profits or settlement of interest expenses	52,050,486.65	27,697,403.47
Including: Cash payments for distribution of dividends or profits to minority shareholders of subsidiaries	-	-
Other cash payments relating to financing activities	37,854,029.00	79,669,279.63
Sub-total of cash outflow from financing activities	1,033,401,651.88	496,595,535.82
Net cash flow from financing activities	900,030,196.23	441,194,302.68

IV. Effect of foreign exchange rate changes on cash and cash equivalents	-6,855,136.19	21,536,381.05
V. Net increase in cash and cash equivalents	-1,303,807,774.24	-1,855,217,755.06
Add: Balance of cash and cash equivalents at the beginning of the period	3,778,142,035.88	5,996,935,997.83
VI. Balance of cash and cash equivalents at the end of the period	2,474,334,261.64	4,141,718,242.77

Legal Representative:
Xiong Jun

Chief Financial Officer:
Xu Baohong

Head of Accounting Department:
Cai Jingwu

New accounting standards or interpretations of standards in 2024 involving adjustments made to initial adoption of relevant items of the financial statements as at the beginning of the year

Applicable Not applicable

Announcement is hereby given.

Shanghai Junshi Biosciences Co., Ltd.*
Board of Directors
29 October 2024